[Evaluation considerations for using surrogate endpoints in anticancer clinical trials].

Song, Y Y; Tang, L; Xia, L; Hao, R M; Yang, Z M

Song, Y Y; Tang, L; Xia, L; Hao, R M; Yang, Z M.

Afiliação

Song YY; Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Tang L; Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Xia L; Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Hao RM; Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Yang ZM; Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.

Zhonghua Zhong Liu Za Zhi ; 44(11): 1155-1159, 2022 Nov 23.

Article em Zh | MEDLINE | ID: mdl-36380663

Assuntos

Antineoplásicos; Neoplasias; Humanos; Neoplasias/terapia; Antineoplásicos/uso terapêutico; Biomarcadores

Palavras-chave

Anti-cancer drugs; Clinical trial; Drug evaluation; Surrogate endpoints

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: Zh Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google